Current Clinical Trials

  • DEP® docetaxel – Phase 2
  • DEP® cabazitaxel – Phase 1 / 2
  • DEP® irinotecan – Phase 1 / 2 

DEP® docetaxel – Phase 2

Status: Recruiting patients

  • Open-label, two-stage design
  • Objectives are to establish anti-tumour activity (efficacy) and safety of DEP® docetaxel (at the Recommended phase 2 Dose (RP2D) of 60mg/m2)
  • First stage to enrol ~20 patients with either lung or prostate cancer (the key approved indications for standard docetaxel (e.g. Taxotere®))
  • Second stage to enrol a further 20 patients (tumour types based on results from the first stage)
  • Also investigating the potential benefits of combining DEP® docetaxel with another anti-cancer agent, nintedanib (Vargatef®)

Download: DEP docetaxel positive phase 1 results; phase 2 commences (pdf, 363kb)

Download: DEP® docetaxel and gemcitabine combination trial commences (pdf 67kb) 

DEP® cabazitaxel - Phase 1 / 2

Status: Recruiting patients

  • Open-label, two-part study (phase 1: open label dose escalation & phase 2: dose expansion to establish efficacy)
  • Objectives are to define the maximum tolerated dose (MTD) to establish safety and explore anti-tumour activity (efficacy) of DEP® cabazitaxel
  • Planning to enrol approximately 35 patients across the phase 1 / 2 trial, with the trial being conducted at multiple sites including Guy’s Hospital London and University College London Hospital

Download: Starpharma to commence DEP cabazitaxel phase 1 / 2 trial (pdf, 147kb)

 

DEP® irinotecan - Phase 1 / 2

Status: Recruiting patients

  • Open-label, two-part study (phase 1: open label dose escalation & phase 2: dose expansion to establish efficacy)
  • Objectives are to evaluate the safety, tolerability and pharmacokinetics of DEP® irinotecan to define a recommended phase 2 dose (RP2D), and to determine anti-tumour efficacy of the product in select tumour types
  • Planning to enrol approximately ~40-45 patients across the phase 1 / 2 trial; initial trial sites include The Christie, Newcastle Freeman Hospital and The Royal Marsden

Download: Starpharma commences phase 1/2 DEP® irinotecan trial (pdf, 147kb)

Download: DEP® irinotecan phase 2 commences after positive phase 1 results (pdf file, 109kb)